Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Phase 1 Completed 18 enrolled Memorial Sloan Kettering Cancer Center Massachusetts General Hospital · collab Weill Medical College of Cornell University · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test whether it is safe to give phenformin with the standard drug combination of one of 3 FDA-approved combinations of BRAF inhibitor + MEK inhibitor which are standard treatments for patients with metastatic melanoma whose melanoma has a mutation in a gene called BRAF.

Timeline

Start: 2017-01
Primary completion: 2025-01-21
Completion: 2025-01-21

Publications

Dalton KM, Lochmann TL, Floros KV, Calbert ML, Kurupi R, Stein GT, McClanaghan J, Murchie E, Egan RK, Greninger P, Dozmorov M, Ramamoorthy S, Puchalapalli M, Hu B, Shock L, Koblinski J, Glod J, Boikos SA, Benes CH, Faber AC. Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma. Proc Natl Acad Sci U S A. 2021 Mar 30;118(13):e2009620118. doi: 10.1073/pnas.2009620118.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Phenformin	Small molecule	100 mg	—
Background	Dabrafenib	Small molecule	150 mg	Oral
Background	Trametinib	Small molecule	2 mg	Oral

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Summary

Timeline

Publications

Drugs

Indications